CONTEXT: Animal studies have demonstrated a role for substance P binding to neurokinin-1 receptor in the pathogenesis of acute pancreatitis. OBJECTIVE: Our aim was to assess the efficacy of a neurokinin-1 receptor antagonist (aprepitant) at preventing post-ERCP pancreatitis in high risk patients. DESIGN: Randomized, double-blind, placebo controlled trial at a single academic medical center. INTERVENTION: Patients at high risk for post-ERCP pancreatitis received either placebo or oral aprepitant administered 4 hours prior to ERCP, 80 mg 24 hours after the first dose, and then 80 mg 24 hours after the second dose. PATIENTS: Thirty-four patients received aprepitant and 39 patients received placebo. STATISTICS: Fisher's exact test was used to compare incidence of post-ERCP pancreatitis in the two groups. RESULTS: Baseline characteristics were similar between the two groups. Incidence of acute pancreatitis was 7 in the aprepitant group and 7 in the placebo group. Hospitalization within 7 days post-procedure for abdominal pain that did not meet criteria for acute pancreatitis occurred in 6 and 9 patients in the aprepitant and placebo groups respectively (P=0.772). CONCLUSIONS: Aprepitant did not lower incidence of post-ERCP pancreatitis in this preliminary human study. Larger studies potentially using the recently available intravenous formulation are necessary to conclusively clarify the efficacy of aprepitant in this setting.
RCT Entities:
CONTEXT: Animal studies have demonstrated a role for substance P binding to neurokinin-1 receptor in the pathogenesis of acute pancreatitis. OBJECTIVE: Our aim was to assess the efficacy of a neurokinin-1 receptor antagonist (aprepitant) at preventing post-ERCP pancreatitis in high risk patients. DESIGN: Randomized, double-blind, placebo controlled trial at a single academic medical center. INTERVENTION: Patients at high risk for post-ERCP pancreatitis received either placebo or oral aprepitant administered 4 hours prior to ERCP, 80 mg 24 hours after the first dose, and then 80 mg 24 hours after the second dose. PATIENTS: Thirty-four patients received aprepitant and 39 patients received placebo. STATISTICS: Fisher's exact test was used to compare incidence of post-ERCP pancreatitis in the two groups. RESULTS: Baseline characteristics were similar between the two groups. Incidence of acute pancreatitis was 7 in the aprepitant group and 7 in the placebo group. Hospitalization within 7 days post-procedure for abdominal pain that did not meet criteria for acute pancreatitis occurred in 6 and 9 patients in the aprepitant and placebo groups respectively (P=0.772). CONCLUSIONS: Aprepitant did not lower incidence of post-ERCP pancreatitis in this preliminary human study. Larger studies potentially using the recently available intravenous formulation are necessary to conclusively clarify the efficacy of aprepitant in this setting.
Authors: J Shawn Mallery; Todd H Baron; Jason A Dominitz; Jay L Goldstein; William K Hirota; Brian C Jacobson; Jonathan A Leighton; Hareth M Raddawi; John J Varg; J Patrick Waring; Robert D Fanelli; Jo Wheeler-Harbough; Glenn M Eisen; Douglas O Faigel Journal: Gastrointest Endosc Date: 2003-05 Impact factor: 9.427
Authors: Shailesh V Shrikhande; Helmut Friess; Fabio F di Mola; Adrien Tempia-Caliera; José R Conejo Garcia; Zhaowen Zhu; Arthur Zimmermann; Markus W Büchler Journal: Pain Date: 2001-04 Impact factor: 6.961
Authors: Jaimie D Nathan; Ruth Y Peng; Yu Wang; Douglas C McVey; Steven R Vigna; Rodger A Liddle Journal: Am J Physiol Gastrointest Liver Physiol Date: 2002-10 Impact factor: 4.052
Authors: Thomas Rabenstein; Bernhard Fischer; Volkmar Wiessner; Harald Schmidt; Martin Radespiel-Tröger; Jürgen Hochberger; Steffen Mühldorfer; Gerhard Nusko; Helmut Messmann; Jürgen Schölmerich; Hans-Joachim Schulz; Herbert Schönekäs; Eckhart Gustav Hahn; Hans Thomas Schneider Journal: Gastrointest Endosc Date: 2004-05 Impact factor: 9.427
Authors: Fariborz Mansour-Ghanaei; Farahnaz Joukar; Ali Akbar Khalesi; Mohammadreza Naghipour; Masood Sepehrimanesh; Kourosh Mojtahedi; Sara Yeganeh; Hamid Saeidi Saedi; Saba Fakhrieh Asl Journal: Ann Hepatobiliary Pancreat Surg Date: 2020-08-31